§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇸🇬Singapore	🇬🇧United Kingdom
Authority & dossier
Regulatory authority	HSA	MHRA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	Available
Reference agencies	FDA, EMA (centralised), MHRA, Health Canada +3	FDA, EMA, Health Canada, Swissmedic +4
Lead pathway (timeline & fees) — Full Evaluation Route (NDA) · International Recognition Procedure (IRP)
Pathway name	Full Evaluation Route (NDA)	International Recognition Procedure (IRP)
Approval timeline	270–365 days	60–110 days
Application fee	SGD 110,000	GBP 35,305
Annual renewal	SGD 4,500	GBP 0
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Not required	Not required
MAH & local presence
Local entity required	Yes	Yes
Local responsible person	Yes	Yes
RP role	A Qualified Person responsible for pharmacovigilance and a Recall Coordinator must be designated by the Registrant. Registered Pharmacist required for the Dealer's Licence.	Qualified Person (Pharmacovigilance) — QPPV — must reside in the UK or EEA. UK Responsible Person (Import) for batch certification of products imported into GB. Local pharmacovigilance contact in the UK required for risk minimisation activities.
Accelerated pathways
Designations available	3 designations	4 designations
Examples	Priority Review, Project Orbis Participation, Pandemic Special Access Route (PSAR)	Early Access to Medicines Scheme (EAMS), Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +1
Post-approval lifecycle
Variations framework	Post-approval changes classified as Major Variation Application (MAV-1, MAV-2), Minor Variation Application (MIV), and Notifications, broadly aligned with EU Type IA/IB/II framework. ASEAN ACTR (Common Technical Requirements) variations classification adopted.	Variations classified per UK Variations Regulations (mirroring EU Reg 1234/2008): Type IA, IAIN, IB, II, and Extensions. MHRA Worksharing available for grouped variations across multiple authorisations.
Renewal cycle	Marketing authorisations valid initially for 1 year (provisional) or 5 years (full); renewal application 6 months before expiry. Most products renewed for indefinite period after first renewal.	Initial 5-year renewal; thereafter MA is granted for unlimited duration unless MHRA determines on PV grounds that one further 5-year renewal is justified.
Pharmacovigilance	Pharmacovigilance under HSA Vigilance & Compliance Branch. PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via PRISM. Singapore is a WHO-UMC member.	MHRA operates the Yellow Card Scheme for ADR reporting. PSURs follow the EU Reference Date list pre-Brexit, with MHRA UK-specific PSUR list since 2021. RMPs required for new MAs and significant variations. Black triangle (▼) for additional monitoring.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	30–60 days	30–60 days
GCP standard	ICH-GCP	ICH E6(R3) (MHRA adopted via Good Clinical Practice Guide; UK statutory instruments 2004/1031 as amended)
Pricing & reimbursement
Price regulation	Free pricing	Regulated
Reference pricing	No	No
HTA required	Yes	Yes
HTA body	Agency for Care Effectiveness (ACE)	NICE (England, Wales, NI), SMC (Scotland), AWMSG (Wales)

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

SingaporeHSA
United KingdomMHRA

English submissions

SingaporeYes
United KingdomYes

CTD accepted

SingaporeYes
United KingdomYes

eCTD accepted

SingaporeYes
United KingdomYes

Reliance pathway

SingaporeAvailable
United KingdomAvailable

Reference agencies

SingaporeFDA, EMA (centralised), MHRA, Health Canada +3
United KingdomFDA, EMA, Health Canada, Swissmedic +4

Lead pathway (timeline & fees) — Full Evaluation Route (NDA) · International Recognition Procedure (IRP)

Pathway name

SingaporeFull Evaluation Route (NDA)
United KingdomInternational Recognition Procedure (IRP)

Approval timeline

Singapore270–365 days
United Kingdom60–110 days

Application fee

SingaporeSGD 110,000
United KingdomGBP 35,305

Annual renewal

SingaporeSGD 4,500
United KingdomGBP 0

Local representative

SingaporeRequired
United KingdomNot required

Local manufacturing

SingaporeNot required
United KingdomNot required

GMP inspection

SingaporeNot required
United KingdomNot required

MAH & local presence

Local entity required

SingaporeYes
United KingdomYes

Local responsible person

SingaporeYes
United KingdomYes

RP role

SingaporeA Qualified Person responsible for pharmacovigilance and a Recall Coordinator must be designated by the Registrant. Registered Pharmacist required for the Dealer's Licence.
United KingdomQualified Person (Pharmacovigilance) — QPPV — must reside in the UK or EEA. UK Responsible Person (Import) for batch certification of products imported into GB. Local pharmacovigilance contact in the UK required for risk minimisation activities.

Accelerated pathways

Designations available

Singapore3 designations
United Kingdom4 designations

Examples

SingaporePriority Review, Project Orbis Participation, Pandemic Special Access Route (PSAR)
United KingdomEarly Access to Medicines Scheme (EAMS), Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +1

Post-approval lifecycle

Variations framework

SingaporePost-approval changes classified as Major Variation Application (MAV-1, MAV-2), Minor Variation Application (MIV), and Notifications, broadly aligned with EU Type IA/IB/II framework. ASEAN ACTR (Common Technical Requirements) variations classification adopted.
United KingdomVariations classified per UK Variations Regulations (mirroring EU Reg 1234/2008): Type IA, IAIN, IB, II, and Extensions. MHRA Worksharing available for grouped variations across multiple authorisations.

Renewal cycle

SingaporeMarketing authorisations valid initially for 1 year (provisional) or 5 years (full); renewal application 6 months before expiry. Most products renewed for indefinite period after first renewal.
United KingdomInitial 5-year renewal; thereafter MA is granted for unlimited duration unless MHRA determines on PV grounds that one further 5-year renewal is justified.

Pharmacovigilance

SingaporePharmacovigilance under HSA Vigilance & Compliance Branch. PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via PRISM. Singapore is a WHO-UMC member.
United KingdomMHRA operates the Yellow Card Scheme for ADR reporting. PSURs follow the EU Reference Date list pre-Brexit, with MHRA UK-specific PSUR list since 2021. RMPs required for new MAs and significant variations. Black triangle (▼) for additional monitoring.

Unlicensed access

Named Patient Supply

SingaporeAvailable
United KingdomAvailable

Compassionate Use

SingaporeAvailable
United KingdomAvailable

Emergency Import

SingaporeAvailable
United KingdomAvailable

Parallel Import

SingaporePermitted
United KingdomPermitted

Clinical trials

CTA approval

SingaporeRequired
United KingdomRequired

Ethics approval

SingaporeYes
United KingdomYes

CTA timeline

Singapore30–60 days
United Kingdom30–60 days

GCP standard

SingaporeICH-GCP
United KingdomICH E6(R3) (MHRA adopted via Good Clinical Practice Guide; UK statutory instruments 2004/1031 as amended)

Pricing & reimbursement

Price regulation

SingaporeFree pricing
United KingdomRegulated

Reference pricing

SingaporeNo
United KingdomNo

HTA required

SingaporeYes
United KingdomYes

HTA body

SingaporeAgency for Care Effectiveness (ACE)
United KingdomNICE (England, Wales, NI), SMC (Scotland), AWMSG (Wales)